Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CUBICIN RF Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Cubicin Rf patents expire, and when can generic versions of Cubicin Rf launch?

Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-one patent family members in twenty-eight countries.

The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

Drug patent expirations by year for CUBICIN RF
Recent Clinical Trials for CUBICIN RF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Poitiers University HospitalPhase 3
University Hospital Inselspital, BernePhase 1
Cubist Pharmaceuticals LLCN/A

See all CUBICIN RF clinical trials

Recent Litigation for CUBICIN RF

Identify potential future generic entrants

District Court Litigation
Case NameDate
CUBIST PHARMACEUTICALS LLC v. CIPLA USA INC.2019-05-24

See all CUBICIN RF litigation

Pharmacology for CUBICIN RF
Synonyms for CUBICIN RF
103060-53-3
Cidecin
CS-1857
Cubicin
Cubicin (TN)
D01080
D4229
Dapcin
Daptomicina
Daptomicina [Spanish]
DAPTOMYCIN
Daptomycin (JAN/USAN/INN)
Daptomycin [USAN:INN:BAN]
Daptomycin for injection
Daptomycine
Daptomycine [French]
Daptomycinum
Daptomycinum [Latin]
Deptomycin
EX-A1967
HY-B0108
LY 146032
LY-146032
LY146032
MK-3009
MolPort-046-033-485
NWQ5N31VKK
SCHEMBL13491700
UNII-NWQ5N31VKK
Paragraph IV (Patent) Challenges for CUBICIN RF
Tradename Dosage Ingredient NDA Submissiondate
CUBICIN POWDER;IV (INFUSION) daptomycin 021572 2008-11-19
CUBICIN POWDER;INTRAVENOUS daptomycin 021572 2008-11-19
CUBICIN RF POWDER;INTRAVENOUS daptomycin 021572 2008-11-19

US Patents and Regulatory Information for CUBICIN RF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CUBICIN RF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1115417 06C0022 France   Start Trial PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
1115417 SPC/GB06/024 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
1115417 SZ 22/2006 Austria   Start Trial PRODUCT NAME: DAPTOMYCIN
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
AstraZeneca
Johnson and Johnson
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.